BRAX Share Price Performance
CA$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Braxia Scientific Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
BRAX Community Narratives
There are no narratives available yet.
Recent BRAX News & Updates
Braxia Scientific Corp. Key Details
Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.034
- Gross Margin
- 14.67%
- Net Profit Margin
- -436.37%
- Debt/Equity Ratio
- -29.6%
Braxia Scientific Corp. Competitors
Snowflake Analysis
About BRAX
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. The company is headquartered in Toronto, Ontario.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Canadian Market Performance
- 7 Days: -1.5%
- 3 Months: 8.0%
- 1 Year: 18.8%
- Year to Date: 18.4%
Over the last 7 days, the market has dropped 1.5%, driven by a pullback of 2.0% in the Financials sector. In the last year, the market is actually up 19%. Earnings are forecast to grow by 11% annually. Market details ›